Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16,551 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells.
Cui Q, Shibata H, Oda A, Amou H, Nakano A, Yata K, Hiasa M, Watanabe K, Nakamura S, Miki H, Harada T, Fujii S, Kagawa K, Takeuchi K, Ozaki S, Matsumoto T, Abe M. Cui Q, et al. Among authors: watanabe k. Int J Hematol. 2011 Jul;94(1):63-70. doi: 10.1007/s12185-011-0885-9. Epub 2011 Jun 23. Int J Hematol. 2011. PMID: 21698356
KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts.
Miki H, Ozaki S, Nakamura S, Oda A, Amou H, Ikegame A, Watanabe K, Hiasa M, Cui Q, Harada T, Fujii S, Nakano A, Kagawa K, Takeuchi K, Yata K, Sakai A, Abe M, Matsumoto T. Miki H, et al. Among authors: watanabe k. Br J Haematol. 2011 Nov;155(3):328-39. doi: 10.1111/j.1365-2141.2011.08844.x. Epub 2011 Sep 9. Br J Haematol. 2011. PMID: 21902681 Free article.
A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration.
Amachi R, Hiasa M, Teramachi J, Harada T, Oda A, Nakamura S, Hanson D, Watanabe K, Fujii S, Miki H, Kagawa K, Iwasa M, Endo I, Kondo T, Yoshida S, Aihara KI, Kurahashi K, Kuroda Y, Horikawa H, Tanaka E, Matsumoto T, Abe M. Amachi R, et al. Among authors: watanabe k. Oncotarget. 2016 Oct 25;7(43):70447-70461. doi: 10.18632/oncotarget.11927. Oncotarget. 2016. PMID: 27626482 Free PMC article.
TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects.
Tenshin H, Teramachi J, Oda A, Amachi R, Hiasa M, Bat-Erdene A, Watanabe K, Iwasa M, Harada T, Fujii S, Kagawa K, Sogabe K, Nakamura S, Miki H, Kurahashi K, Yoshida S, Aihara K, Endo I, Tanaka E, Matsumoto T, Abe M. Tenshin H, et al. Among authors: watanabe k. Blood Adv. 2017 Oct 26;1(24):2124-2137. doi: 10.1182/bloodadvances.2017008813. eCollection 2017 Nov 14. Blood Adv. 2017. PMID: 29296860 Free PMC article.
Reveromycin A, a novel acid-seeking agent, ameliorates bone destruction and tumor growth in multiple myeloma.
Watanabe K, Bat-Erdene A, Tenshin H, Cui Q, Teramachi J, Hiasa M, Oda A, Harada T, Miki H, Sogabe K, Oura M, Sumitani R, Mitsui Y, Endo I, Tanaka E, Kawatani M, Osada H, Matsumoto T, Abe M. Watanabe K, et al. Haematologica. 2021 Apr 1;106(4):1172-1177. doi: 10.3324/haematol.2019.244418. Haematologica. 2021. PMID: 32586903 Free PMC article. No abstract available.
Long-term Management of a Patient with Apert Syndrome.
Horiuchi S, Sato H, Iwasa A, Ichihara A, Tenshin H, Watanabe K, Hiasa M, Hashimoto I, Tanaka E. Horiuchi S, et al. Among authors: watanabe k. J Contemp Dent Pract. 2021 Oct 1;22(10):1184-1190. J Contemp Dent Pract. 2021. PMID: 35197388
Nonsurgical orthodontic treatment for a patient with Sotos syndrome.
Shioyasono R, Yoshinaga K, Shioyasono A, Ito A, Watanabe K, Hiasa M, Horiuchi S, Tanaka E. Shioyasono R, et al. Among authors: watanabe k. Am J Orthod Dentofacial Orthop. 2023 Mar;163(3):426-442. doi: 10.1016/j.ajodo.2021.11.021. Epub 2022 Nov 24. Am J Orthod Dentofacial Orthop. 2023. PMID: 36437146
16,551 results
You have reached the last available page of results. Please see the User Guide for more information.